Receptor binding, G proteins and second messengers — the mechanism behind why peptides work at tiny quantities.
A peptide has a shape. That shape is the whole mechanism.
Each peptide folds into a particular shape. That shape comes from the order of its amino acids. Cells carry receptors on their surface, and each receptor has a shape of its own.
When a peptide meets a receptor it fits, it binds. When it meets one it does not fit, nothing happens. That is where the precision comes from. A peptide aimed at one pathway leaves the others alone, because it cannot attach to the wrong receptor.
For most peptide hormones, the receptor is a type called a G protein coupled receptor, usually shortened to GPCR.
Binding changes the receptor's shape. That change switches on a G protein sitting inside the cell. The G protein then triggers a second messenger, usually cyclic AMP. The second messenger sets off a chain of reactions inside the cell.
Notice what that chain does to the numbers. One peptide binds one receptor. That makes many second messenger molecules, and each one drives further reactions. The signal grows at every step.
That amplification is why peptides can act at very small quantities. The peptide is not doing the work. It is starting something that does the work.
"Most peptide receptors are GPCRs" is a useful rule. It has a famous exception, and it is the peptide everyone names first.
The insulin receptor is not a GPCR. It belongs to a different family, called receptor tyrosine kinases, which signals a different way. So the best-known peptide hormone does not follow the best-known mechanism. Worth knowing before you lean on the rule.
This article explains published research and the rules around it. It carries no dose, no protocol, and no claim that any compound treats, cures or prevents a condition in anyone. Where the evidence is thin we say so. See our editorial standards.
KLOW is GLOW plus 10 mg of KPV — that part is simple. The more useful fact is that both are, by mass, mostly copper peptide, and that is the ingredient whose injected form has no human trials.
An open study found sleep normalised in six of seven patients. The controlled study by the same investigator found weak effects and said so. The difference between them is a placebo arm.
It does not raise dopamine — it magnifies what other things do to it. That one property explains why caffeine feels stronger on it, and why MAO inhibitors are a hard contraindication.
